依达拉奉联合尤瑞克林治疗急性脑梗死疗效及对患者C反应蛋白、神经功能缺损评分影响

目的：观察依达拉奉联合尤瑞克林治疗急性脑梗死的疗效,以及对患者C反应蛋白（CRP）、神经功能缺损评分（NIHSS）的影响。方法：88例急性脑梗死患者随机分为观察组和对照组。对照组予依达拉奉及常规阿司匹林、阿托伐他汀治疗,观察组在对照组基础上加用尤瑞克林。对比两组患者治疗前及治疗后第7天、第14天的CRP水平及NIHSS评分,比较两组患者治疗后3月的临床疗效及治疗后的药品不良反应发生率。结果：两组患者治疗后第7天、第14天CRP水平与NIHSS评分均有显著下降（P〈0.01）;且观察组治疗后第7天、第14天的CRP水平与NIHSS评分均显著低于对照组（P〈0.01）。观察组临床总有效率为93.18%,明显高于对照组的88.63%（P〈0.05）。两组药品不良反应发生率比较,差异无统计学意义（P〉0.05）。结论：依达拉奉联合尤瑞克林治疗急性脑梗死疗效优于单用依达拉奉,可改善患者预后,值得临床推广。

Curative Effect of Edarovone Combined with Urinary Kallidinogenase in Patients with Acute Cerebral Infarction and the Influence on C-reactive Protein and Nerve Function Score

Objective：To observe the influence of edaravone combined with urinary kallidinogenase on C-reactive protein （CRP） , Nerve function score （national institutes of health stroke scale, NIHSS） in patients with acute cerebral infarction. Methods： 88 patients with acute cerebral infarction were randomly divided into observation group and control group. The control group received regular edaravone ,aspirin and atorvastatin ,while the observation group were added uri- nary kallidinogenase on the basis of the medicine used in control group. By comparison of the CRP levels and NIHSS score in two groups of patients before and after seven days, 14 days of treatment. Besides, the clinical efficacy and drug treatment after 3 months,,as well as the incidence of adverse reactions were also compared. Results： The CRP levels and NIHSS scores after seven days and 14 days of treatment were decreased significantly, both groups of patients （P 〈 0.01 ）. The CRP levels and NIHSS scores after seven days and 14 days of treatment in the observation group were significantly lower than in the control group（ P 〈 0.01 ）. After three months in the observation group therapy clinical the total effective rate was 93.18% which was higher than the rate of control group（ 88.63% ） （P 〈 0.05 ）. The incidence of adverse drug reactions both groups, the difference was not statistically significant（ P 〉 0.05 ）. Conclusion ： The edaravone combined with urinary kallidinogenase for acute cerebral infarction is better than single edaravone. It can improve the prognosis of patients, which is worthy of promotion.